Notice for nivolumab (Bristol-Myers Squibb Australia Pty Ltd)
Active ingredients
nivolumab
Date of review outcome
Lapse date
Type
Priority review
Indication
Opdivo in combination with ipilimumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma
Therapeutic area
Oncology